Navigation Links
Hyperion Therapeutics Raises $60 Million Series C
Date:6/30/2009

SOUTH SAN FRANCISCO, Calif., June 30 /PRNewswire/ -- Hyperion Therapeutics, a privately held specialty pharmaceutical company focused on the development of therapies that address critical unmet needs in the areas of gastroenterology and hepatology, today announced it has closed a $60 million Series C financing. New investors Bay City Capital and Panorama Capital co-led the financing. Series A and B investors Highland Capital Partners, NEA, and Sofinnova Ventures also participated.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070905/AQW076LOGO)

The Series C financing follows the Company's recent announcement of Phase II results and orphan drug designation for HPN-100 in its lead indication, the chronic treatment of patients with urea cycle disorders (UCD). The capital will fund the Phase III clinical program for UCD as well as a Phase II study in low grade hepatic encephalopathy.

Concurrent with the Series C financing, H. Daniel Perez, M.D. of Bay City Capital, and Gaurav Aggarwal, M.D. of Panorama Capital have joined the Hyperion Therapeutics Board of Directors.

"Considerable unmet needs remain in the treatment of both urea cycle disorders and hepatic encephalopathy," said Daniel Perez of Bay City Capital. "We believe the Hyperion management team, with their extensive drug development and regulatory expertise, is well positioned to lead a clinical development program focused on potential treatment options for these patients."

About HPN-100

HPN-100 is an investigational product that is a pre-pro-drug of phenylacetic acid, the active moiety of BUPHENYL(R), the only therapy currently FDA-approved as adjunctive therapy for the chronic management of patients with the most prevalent urea cycle disorders: carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), and argininosucci
'/>"/>

SOURCE Hyperion Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Hyperion Therapeutics Announces Results of Phase I Study in Patients With Liver Cirrhosis
2. Hyperion Therapeutics Completes Phase 2 Data Analysis and Schedules End of Phase 2 Meeting With FDA for HPN-100 in the Chronic Treatment of Urea Cycle Disorders
3. Hyperion Therapeutics Elects Lota Zoth to Board of Directors
4. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy
5. Cornerstone Therapeutics Joins the Russell 3000(R) Index
6. Global Autoimmune Disease Therapeutics Market to Reach $50 Billion by 2015, According to a New Report by Global Industry Analysts
7. Intrinsic Therapeutics Barricaid and Magellan Spine Technologies DART to Drive European Annulus Repair Market
8. Cell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review
9. Prospect Therapeutics Inc.s GCS-100 Has Focused on Developing Treatment for Three Blood-Borne Cancers
10. Cell Therapeutics Announces Final Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding
11. Transition Therapeutics Announces Appointment of Vice-President of Clinical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2015)... A recent report for Mass Live ... died as a direct result of an opiate overdose in ... rise in overdose deaths attributed to prescription opiate medications, and ... care about geography. This issue doesn’t care about race. This ... class.” As the state of Mass. reels from the effects ...
(Date:5/25/2015)... After the sensational buzz surrounding their ... wellness company Trivedi Master Wellness™ agrees to ... series titled, “Consciousness is Power.” Presently, the Live-Streaming event ... at the routinely allotted time from 10:00pm PST/1:00pm EST ... made available to the public and accessible on the ...
(Date:5/24/2015)... New York, NY (PRWEB) May 24, 2015 ... begins on Sunday, May 24th in San Diego at Petco ... tour throughout North America. On May 20th, they had ... Theatre. At their preview show in Los Angeles, this ... its entirety; they also played fan favorites such as "Jumping ...
(Date:5/24/2015)... 24, 2015 EnviroLeather™ by LDI, ... Plus” – a classic, rugged leather grain with ... difficult stains, including ink, to be easily removed. ... suitable for corporate, healthcare, hospitality and education environments. ... EnviroLeather’s goal of developing products that are more ...
(Date:5/24/2015)... 24, 2015 ... - The students were selected ... the fourth annual A Day of ... Geneva National in Lake Geneva. , ... High School,         Jonathan Alfonso,         Bridget Keefe, ...
Breaking Medicine News(10 mins):Health News:Opioid Deaths Increase by 33 Percent Since 2012 in Mass. 2Health News:Hundreds of People Are Thrilled to Hear that Trivedi Master Wellness™ Promises to Hold Another Workshop in June 2015 2Health News:Hundreds of People Are Thrilled to Hear that Trivedi Master Wellness™ Promises to Hold Another Workshop in June 2015 3Health News:The Rolling Stones Tickets in San Diego, Orlando, Minneapolis, Dallas, Pittsburgh, Indianapolis, Atlanta, Detroit, Milwaukee, Kansas City, Columbus, Nashville & Raleigh 2Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2
... initiated by World Health,Organization's (WHO) authority to ... unofficial,sources, soon after any outbreak of infectious,diseases ... a crucial decision it was decided that ... on-the-spot,investigations to determine the severity of an,outbreak ...
... on its border with hard-hit China. ,The first confirmed case ... the Amur river, which forms the frontier with China, came ... his country could contain the disease.,Hu told students in Moscow, ... introduced strict measures to stop the spread of the deadly ...
... may benefit non-anemic women between ages 18 and 55 with ... with low ferritin, a protein that stores iron and is ... of Lausanne in Switzerland gave 136 women either 80 milligrams ... The study shows the level of fatigue after one month ...
... The global health community has taken a key ... of infectious diseases and other threats to international ... underlines the World Health Organization’s (WHO) authority to ... unofficial sources, and, when necessary to determine the ...
... the illness have been told to quarantine themselves at ... chief medical officer of health. Precautions taken at ... control dozens of possible new cases. Health officials ... city back on its list of SARS - affected ...
... may have a potential role in treating Alzheimer's. Lithium ... of both the proteins found in Alzheimer's patients. Identification ... other drugs that disrupt the production of both proteins., ... not disrupt the processing of another protein called notch, ...
Cached Medicine News:Health News:WHO Says Toronto Going Back on SARS-Affected List 2Health News:Lithium May help in Alzheimer's Disease 2
(Date:5/22/2015)... 22, 2015   InspireMD, Inc. (NYSE MKT: NSPR) ... systems ("EPS"), today announced that its CGuard TM Embolic ... investigator Prof. Piotr Musialek , at the EuroPCR ... France . PARADIGM, an investigator-initiated P ... A roti D revascularization I n symptomatic and ...
(Date:5/22/2015)... 22, 2015 Today, Rhodes Pharmaceuticals L.P. announced ... stimulant indicated for the treatment of Attention-Deficit/Hyperactivity Disorder ... 2015. The announcement comes just ... the U.S. Food and Drug Administration (FDA). ... of methylphenidate capsule with an onset of effect ...
(Date:5/22/2015)... LONDON , May 22, 2015 ... early phase clinical research unit with a worldwide ... respected for its frequent publications in peer reviewed ... and European stakeholders and regulators in discussions about ... results.      (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , ...
Breaking Medicine Technology:InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6
... WASHINGTON, Aug. 10, 2011 In a just-released National ... Treatment http://www.nmqf.org/IB3SpecialtyTiersFinal.pdf ), Gary Puckrein ... has become popular among insurers (public and private) as ... requiring beneficiaries to pay more for certain high-cost prescription ...
... and ST. AUGUSTINE, Fla., Aug. 10, 2011 ... hospitals, has selected the Sunrise Enterprise ™ suite ... (NASDAQ: MDRX).  In addition to implementing Sunrise within the ... Electronic Health Record (EHR) and practice management solution ...
Cached Medicine Technology:Prescription-Drug Plans' Use of Specialty Tiers Promotes Inequalities 2Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 2Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 3Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 4Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 5Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 6
The playful pattern of this lens features sky-blue forms fanning out from the center of your eye....
Each jet black lens features a mesmerizing thin white line that spirals toward the center of the pupil....
The opaque outer circle will white-out even the darkest iris, making your pupil the only spot of black in a sea of white....
Yellow flames radiate out from the center of eye, held in check by the fire-engine red perimeter....
Medicine Products: